Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Epigenomics|August 12, 2014
EZH2 as a potential target in cancer therapyMichael T McCabe, Caretha L Creasy
Nature Medicine|March 8, 2019
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancerHelai P Mohammad, Olena Barbash, Caretha L Creasy
The Journal of Biological Chemistry|February 7, 2013
The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylation and inactivation of peroxiredoxin-1 proteinSonali Jalan Rawat, Caretha L Creasy, Jeffrey R Peterson, et al.
Current Genetics|April 2, 2004
The yeast Pho80-Pho85 cyclin-CDK complex has multiple substratesNorman C Waters, Janine P Knight, Caretha L Creasy, et al.
ACS Chemical Biology|December 6, 2013
Long residence time inhibition of EZH2 in activated polycomb repressive complex 2Glenn S Van Aller, Melissa Baker Pappalardi, Heidi M Ott, et al.
Nature Communications|January 23, 2015
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressorsDaniel Zingg, Julien Debbache, Simon M Schaefer, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 7, 2011
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesHua Li, Benjamin G Bitler, Vinod Vathipadiekal, et al.
Molecular Cancer Therapeutics|September 26, 2014
A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylationHeidi M Ott, Alan P Graves, Melissa B Pappalardi, et al.
Oncotarget|December 3, 2013
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerAnastasia Wyce, Yan Degenhardt, Yuchen Bai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid TumorsTimothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Pageof 7